Back to Journals » Drug Design, Development and Therapy » Volume 5

Clinical utility of clodronate in the prevention and management of osteoporosis in patients intolerant of oral bisphosphonates

Authors Muratore M, Quarta E, Grimaldi A, Calcagnile F, Quarta L

Published 19 October 2011 Volume 2011:5 Pages 445—454

DOI https://doi.org/10.2147/DDDT.S12139

Review by Single-blind

Peer reviewer comments 4


Maurizio Muratore, Eugenio Quarta, Antonella Grimaldi, Fabio Calcagnile, Laura Quarta
Department of Rheumatology, Hospital Galateo, San Cesario di Lecce, Italy

Abstract: Bisphosphonates have a long history in the treatment of osteoporosis and bone-related disease. This review focuses on the use of a specific nonaminobisphosphonate, clodronate, which appears to be much better tolerated than other bisphosphonates and free of high-risk contraindications. Specifically, this paper reviews its use in the prevention of osteoporosis in postmenopausal women, taking into account its tolerability profile and recent safety issues arising regarding the use of bisphosphonates.

Keywords: clodronate, bisphosphonates, osteoporosis, bone turnover, menopause, tolerability

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]